Your AI-Trained Oncology Knowledge Connection!
Seema A. Bhat, MD, is a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University
Dr Bhat on Selecting Between Liso-Cel and Pirtobrutinib in Relapsed/Refractory CLL
Seema A. Bhat, MD, discusses selecting between liso-cel and pirtobrutinib in relapsed/refractory CLL.
Read More
Dr Bhat on Choosing Between Pirtobrutinib and Liso-Cel for R/R CLL Management
Seema A. Bhat, MD, discusses disease features and patient characteristics that inform the choice between pirtobrutinib and liso-cel for CLL.
Dr Bhat on Using BTK Degraders and Bispecific Antibodies to Address Challenges With R/R CLL Management
Seema A. Bhat, MD, discusses the ongoing development of BTK degraders and novel bispecific antibodies in relapsed/refractory CLL.
Dr Bhat on the Limitations of Current Treatments for Double-Refractory CLL
Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.
Dr Bhat on the Influence of MPN Risk Stratification on Treatment Decision-Making
Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.
Dr. Bhat on ELEVATE-TN Results in Treatment-Naïve CLL
Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.
Dr. Bhat on the FDA Approval of Acalabrutinib in CLL
Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.
Dr. Bhat on the Potential for Time-Limited Combinations in CLL
Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.
Dr. Bhat on Emerging Targeted Therapies in CLL
Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.
Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL
Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.
Dr. Bhat on the Combination of Ibrutinib Plus FCR in Treatment-Naïve CLL
Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.
Dr. Bhat on the Role of Targeted Therapies in CLL
Seema A. Bhat, MD, hematologist, discusses the role of targeted therapies in chronic lymphocytic leukemia.
Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma